Purdue names UConn dean to head Krannert
Purdue University has named P. Christopher Earley, dean at the University of Connecticut School of Business, to take over as dean of Purdue’s Krannert School of Management.
Purdue University has named P. Christopher Earley, dean at the University of Connecticut School of Business, to take over as dean of Purdue’s Krannert School of Management.
Eli Lilly & Co. CEO John C. Lechleiter said Germany’s overhaul of drug pricing lacked transparency and the new policy creates “uncertainty” for the company’s business planning.
Why do drugmakers still pursue so many me-too drugs? Because, if marketed well, they can be extremely lucrative. Just ask Eli Lilly and Co. about its drug Cialis.
Janssen Pharmaceutica said Thursday it has completed the sale of its animal health business to Eli Lilly and Co. Inc.
Lilly executives are emphatic that they have no plans to reduce the company's 49-cents-a-share quarterly cash dividend, which gives the stock a rich annual yield of 5.2 percent.
Purdue just added a large tenant to the Indianapolis research park, bringing the total to 14.
The High Court in London on Tuesday denied Lilly’s request for a judgment without trial against Neopharma Ltd., the closely held company that has European marketing rights for the generic version of the drug known chemically as olanzapine.
To understand the depths of the pharmaceutical industry’s recent struggles, consider this: The industry has been spending $57 billion more per year on research and development than the value of the products it has been launching. That’s a problem.
Eli Lilly and Co., once the undisputed leader in the U.S. diabetes market, wants to regain its dominance by launching as many as four new diabetes drugs in the next five years, Lilly executives said during an investor meeting June 30. Lilly has lost large chunks of market share in the past decade to Denmark-based Novo Nordisk A/S and France-based Sanofi-Aventis SA. But this year, Lilly, through a partnership with Germany-based launched Boehringer Ingelheim GmbH, launched Tradjenta, a once-daily tablet that will compete with Merck & Co. Inc.’s successful Januvia but could involve fewer complications for patients with liver or kidney problems. As early as next year, Lilly could get the green light on Bydureon, a long-delayed once-weekly version of its Byetta treatment, developed with Amylin Pharmaceuticals Inc. Lilly could seek regulatory approval in 2013 for dulaglutide, a once-a-month drug similar to Bydureon. An oral drug called empagliflozin, also gained through the agreement with Boehringer Ingelheim, could launch in 2014. "Diabetes is one of the great opportunities for Lilly moving forward," Jan Lundberg, president of Lilly Research Laboratories, said in an interview with Reuters.
As part of its agreement to add Westview Hospital to its system, Community Health Network will assume $10 million in debt, spend $7.5 million on upgrades, and help open an outpatient center in Speedway, the two hospitals announced June 28. They will also look for more locations in western Indianapolis to add outpatient centers. Community and Westview first announced in November they were in talks to form a “strategic alliance.” On June 24, Westview’s board approved the merger. Westview needed to get bigger, CEO Jon Anderson said, because the 2010 health care reform law and other national trends are pushing hospitals to have some of their revenue hinge on whether they keep a specific population of patients healthy. Westview had annual revenue of $106 million in 2009, the most recent figure available. Community is more than 10 times as large, with annual revenue of $1.3 billion. From Community’s perspective, Westview helps it expand into the western portion of Indianapolis for the first time. In addition to Anderson, Community has hospitals in the southern, eastern and northeastern suburbs of Indianapolis. Community wants to make sure it has facilities accessible on all sides of the city in order to be attractive to employers who want to contract with a hospital system—either directly or through an insurer—that will take responsibility for keeping the employees healthy.
Indiana University Health is losing its chief financial officer, who has overseen the hospital system’s bulging balance sheet since 1999. Marvin Pember, 58, is taking a new job near Philadelphia as president of the acute care division of Universal Health Services Inc., a publicly traded company with 22 acute hospitals and numerous behavioral health centers spread from coast to coast. Pember’s last day at IU Health will be July 29. IU Health, an 18-hospital system based in Indianapolis, will begin a national search for his replacement immediately. Pember joined IU Health, then known as Clarian Health, when it had just three hospitals—Methodist, Indiana University Hospital and Riley Hospital for Children—all in downtown Indianapolis. Today, its hospitals stretch from LaPorte and Goshen in northern Indiana to Paoli and Bedford in the south. IU Health also has three more facilities set to join its fold by year’s end.
Eli Lilly and Co., the Indianapolis-based drugmaker whose best-selling schizophrenia medicine Zyprexa survived a patent challenge in Britain two years ago, has asked a United Kingdom judge to reject a parallel lawsuit by a generic drug company.
Eli Lilly and Co.’s foray into combination drugs is well-timed because the company could take advantage of some the world’s most successful biotech medicines, which are about to see their patents expire.
The Indiana State Museum begins a new fiscal year Friday with a different governance structure and a $1.1 million surplus.
Despite some post-acquisition stumbles, the moral of the story should not be that Hoosier executives need to proceed with greater caution.
In a monthly feature that runs in the first issue of the month, through October, IBJ is identifying influential players in eight different industry categories. This month, our list draws from among the city’s finest legal minds in education, public-sector law, the judicial system and the broad swath of attorneys practicing solo and in firms of all sizes.
Lilly has 33 drugs in the second and third stages of clinical trials, including medicines for cancer, diabetes and Alzheimer’s disease, up from seven in 2005, the Indianapolis-based company said Thursday.
Indianapolis-based Eli Lilly and Co. raised its spending 8 percent from the $2.3 million that it spent in the first quarter of last year. The drugmaker also spent 70 percent more than the $1.5 million recorded in the final quarter of 2010, according to lobbying reports filed with the House of Representatives.
Indianapolis-based drugmaker Eli Lilly on Tuesday will announce a multimillion-dollar investment to develop drugs that act like two medicines in one. Lilly plans to add more scientists to back the effort.
Indiana has added 220 startups and more than 8,000 jobs in its $27 billion life sciences industry since 2002, according to a report commissioned by BioCrossroads, the Indianapolis-based life sciences development group. Despite the presence of pharmaceutical firms such as Eli Lilly and Co., medical-device manufacturing represented the biggest chunk of employment in Indiana: 20,300, or 35.5 percent, of life sciences workers. Indiana ranks third, behind New Jersey and Massachusetts, in highest quotient of life sciences workers. Though noting Indiana has made big strides to emerge as a national center in the life sciences, the report makes it clear the state still has needs. These include better access to seed/early-stage and venture capital, a more skilled work force and more focus on emerging areas such as health information technology and contract manufacturing.
The U.S. Supreme Court has refused to revive a bid to press a class-action suit against Eli Lilly and Co. over the marketing of the antipsychotic Zyprexa, according to Bloomberg News. A group of pension funds, unions and insurers claimed they represented a class of third-party payors who spent $6.8 billion more on Zyprexa than they should have, because Lilly made fraudulent claims about Zyprexa’s safety and effectiveness and promoted it for non-approved uses. A federal appeals court had said the case wasn’t appropriate for class-action status and told a trial judge to consider whether the plaintiffs filing the suit could press their individual claims. Indianapolis-based Lilly in 2009 pleaded guilty to promoting Zyprexa for unapproved uses and agreed to pay $1.4 billion in criminal and civil penalties.
Wishard Health Services will change its name to Eskenazi Health after receiving a $40 million gift from Indianapolis real estate developer Sidney Eskenazi and his wife, Lois, the county-owned hospital announced June 22. The $754 million hospital Wishard is building downtown will be renamed the Sidney and Lois Eskenazi Hospital when it opens in December 2013. The Eskenazis' gift is the largest in the history of Wishard, which began as City Hospital in 1859 and adopted the Wishard name in 1975. Wishard Foundation was trying to raise $50 million to help fund construction of the new hospital. With the Eskenazis' gift, it has now raised $54 million. Sid Eskenazi, 81, started Sandor Development Co. in 1963 and has grown it into one of the nation’s largest owners of strip malls. Sandor has long-standing relationships with major retailers such as Wal-Mart Stores Inc. and Kohl’s.
Forget this year’s loss of best-selling-drug Zyprexa’s patent. Eli Lilly and Co. faces the bleakest outlook in the pharma industry the rest of this decade, according to Bernstein Research analyst Tim Anderson.
The U.S. Supreme Court has refused to revive a bid to press a $6.8 billion class-action suit against Eli Lilly and Co. over the marketing of Zyprexa, the company’s schizophrenia treatment.